Faster Paths To Biosimilar Equivalence: Turning New US & EU Guidance Into Development Advantage

Recent FDA guidance and anticipated EU direction place greater emphasis on analytical similarity and risk-based justification, creating opportunities to streamline or waive comparative clinical studies when residual uncertainty is sufficiently reduced. Process development teams can respond by integrating advanced analytics, structure-function knowledge, and targeted control strategies earlier in development. This approach can strengthen equivalence demonstrations while supporting faster, more efficient development pathways. Cytiva’s regulatory services help teams interpret FDA expectations, design robust similarity packages, and align development strategies with evolving requirements.

Gain insight into practical strategies for building a compliant, evidence-driven biosimilar development program.